enGene to Participate in Upcoming Investor Conferences

Rhea-AI Summary

enGene Holdings (Nasdaq: ENGN) announced its participation in two upcoming investor conferences. The company's Chief Strategy and Operations Officer, Alex Nichols, Ph.D., will present at the Virtual Citizens JMP Hematology & Oncology Summit on December 2, 2024, at 10:00 a.m. ET, and the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 3:00 p.m. ET.

enGene is developing detalimogene voraplasmid, a non-viral investigational product for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ. The presentations will be available via webcast on the company's website for 90 days.

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will participate in upcoming investor conferences. Details of the conferences are below:

Conference: Virtual Citizens JMP Hematology & Oncology Summit
Date: Monday, December 2, 2024
Time: 10:00 a.m. ET
Format: Corporate Presentation

Conference: Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 3:00 p.m. ET
Format: Fireside Chat

A live webcast of these presentations can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125221097/en/

For media contact: media@engene.com

For investor contact: investors@engene.com

Source: enGene Holdings Inc.

FAQ

When is enGene (ENGN) presenting at the Virtual Citizens JMP Summit in 2024?

enGene (ENGN) will present at the Virtual Citizens JMP Hematology & Oncology Summit on Monday, December 2, 2024, at 10:00 a.m. ET.

What conferences will enGene (ENGN) attend in December 2024?

enGene (ENGN) will attend two conferences: the Virtual Citizens JMP Hematology & Oncology Summit on December 2 and the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024.

What is the main product enGene (ENGN) is developing?

enGene (ENGN) is developing detalimogene voraplasmid, a non-viral investigational product for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

How long will enGene's (ENGN) conference webcasts be available?

The webcasts of enGene's (ENGN) conference presentations will be archived on the company's website for 90 days.